Journal
CANCER CELL
Volume 27, Issue 4, Pages 489-501Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2015.03.004
Keywords
-
Categories
Funding
- National Cancer Institute [NCI CA174795]
- NIH/NIGMS Biotechnology Training Program
- NSF graduate research fellowship
Ask authors/readers for more resources
Cancer immunotherapies under development have generally focused on either stimulating T cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody and an untargeted IL-2 fusion protein with delayed systemic clearance induces significant tumor control in aggressive isogenic tumor models via a concerted innate and adaptive response involving neutrophils, NK cells, macrophages, and CD8(+) T cells. This combination therapy induces an intratumoral cytokine storm'' and extensive lymphocyte infiltration. Adoptive transfer of anti-tumor T cells together with this combination therapy leads to robust cures of established tumors and development of immunological memory.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available